

FROM ACUTE TO FUNCTIONAL RECOVERY

\$6.6 BILLION ACUTE SPINAL CORD INJURY THERAPEUTICS MARKET OPPORTUNITY

Global acute spinal cord injury (SCI) therapeutics market is expected to reach US\$6.6 billion by 2028; North America has the largest market share.

EXOTHERAPY - NUREXONE'S REVOLUTIONARY DRUG PLATFORM

A novel, biological and minimally invasive treatment for spinal cord injuries (SCI)

What is ExoTherapy...?

- **ExoTherapy** is a drug platform that will leverage proprietary extracellular vesicle-based technology to deliver therapeutic compounds to target damaged tissues – reestablishes neural activity and reverses damage to the spinal cord and other Central Nervous System (CNS) indications.
- **ExoPTEN**, the company's first ExoTherapy which can be administered intranasally, uses a therapeutic siRNA compound to decrease the expression of PTEN, a protein that blocks nerve regeneration and prevents recovery.
- **ExoTherapy** was conceptually demonstrated in animal studies and was shown to safely restore motor function in rats with fully transected spines.
- The **exosome-based technology** has been licensed exclusively from two leading Israeli universities.

EXOSOMES: THE FUTURE OF DRUG DELIVERY

Exosomes are biologically-guided nanocarriers. Due to their unique ability to carry “molecular cargo” to a target anatomy while navigating extracellular spaces and penetrating cell membranes, exosomes are considered as a biological drug delivery platform of the future. As a result, pharmaceutical giants such as Roche and Eli Lilly have invested roughly \$1 billion into this space. NurExone holds an exclusive license for manufacture and commercialization of a proprietary exosome process for all clinical indications. NurExone is one of the few publicly listed companies with its own exosome-based technology.

APPLICATION TO OTHER CNS INDICATIONS

Spinal cord injuries were selected as the first indication to be addressed due to the enormous market value, the lack of comparable therapies, and the expected clinical benefits. Beyond damages to the spine, NurExone's exosome manufacturing and therapeutic compound loading technology can serve as a future platform for therapies for other central nervous system (CNS) indications.

SHARE STRUCTURE





Common Shares	42,383,963
Warrants ¹	15,223,806
Options ²	4,151,995
Fully Diluted Share Capital	61,759,764
Insider Ownership	~11%

1. Exercise Price: \$1.20 CAD; expires between June 2023 and May 2024


2. Exercise Price: \$0.80 CAD; expires between August 2031 and January 2032

With over 10 employees, founded in 2020 by Prof. Shulamit Levenberg (Technion, Israel Institute of Technology) and Prof. Daniel Offen (Tel Aviv University) together with serial Bio-Tech entrepreneur Yoram Drucker

Our R&D team consists of PhD's scientific researchers with proven track record and extensive expertise. The Company has a scientific advisory board from various disciplines and Scale R&D facilities around the world.

MRI IMAGING OF MICE SPINAL CORD	TIMING	POST 56 DAYS
	Beginning of experiment	Full functionality
	Following the complete transection of the spinal cord	Full paralysis
	Exosome only (control)	None
	Intranasal Exo-PTEN administration – synergistic between control group	Restored functionality

- Full spinal cord transection and intranasal administration of the ExoPTEN
- Biologically guided to injured tissue
- **Nurexone's ExoTherapy** led to significant functional recovery
- Functional recovery was accompanied by motor and sensors improvement and faster urine bladder restoration




MILESTONES AND CATALYSTS 2022

- List on a recognized Canadian junior stock exchange to gain broader capital market awareness
- Secure new patents to increase expand technology platform and competitive moat
- Complete the development of a state-of-the-art R&D facility owned by NurExone
- Sign collaboration agreement with leading companies for the development of the non-invasive administration of ExoTherapy for spinal cord injuries
- Advance M&A program by evaluating various accretive acquisition opportunities

OUR EXPANDING IP PORTFOLIO

- Intranasal ExoPTEN (PCT)
- 2 PCTs – on Production and Composition of Matter of our exosomes
- 4 provisionals on loading technique and siRNA target sequences

ROAD MAP



FOR MORE INFORMATION:

www.nurexone.com | ir@nurexone.com | 9 Mezada Street BSR 3 Tower, 30 Fl. Bnei-Brak, Israel